Overview

Intravenous Iron Metabolism in Restless Legs Syndrome

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
To determine the effects of high-dose infusions of iron on Restless Legs Syndrome (RLS) symptoms and brain concentrations of iron.
Phase:
Phase 2
Details
Lead Sponsor:
American Regent, Inc.
Luitpold Pharmaceuticals
Collaborator:
National Institute on Aging (NIA)
Treatments:
Iron